Zimmer Biomet Holdings Inc. (NYSE:ZBH) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $131.59 and last traded at $131.06, with a volume of 299,394 shares changing hands. The stock had previously closed at $130.91.

A number of research analysts have weighed in on ZBH shares. Morgan Stanley reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Saturday, April 30th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Saturday, April 30th. Barclays PLC reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Saturday, April 30th. Jefferies Group reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Sunday, May 22nd. Finally, Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $130.45.

The firm’s 50 day moving average is $123.20 and its 200-day moving average is $111.74. The firm has a market capitalization of $26.20 billion and a PE ratio of 120.00.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, July 28th. The company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.97 by $0.05. The business had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.90 billion. The firm’s revenue for the quarter was up 65.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.58 EPS. Equities research analysts forecast that Zimmer Biomet Holdings Inc. will post $7.97 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, July 29th. Investors of record on Friday, June 24th were issued a dividend of $0.24 per share. The ex-dividend date was Wednesday, June 22nd. This represents a $0.96 dividend on an annualized basis and a yield of 0.73%.

In other Zimmer Biomet Holdings news, insider David A. Jr. Nolan sold 25,255 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $130.77, for a total transaction of $3,302,596.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Stuart G. Kleopfer sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $119.45, for a total value of $1,313,950.00. Following the transaction, the insider now owns 7,609 shares in the company, valued at approximately $908,895.05. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently bought and sold shares of ZBH. Employees Retirement System of Texas purchased a new position in Zimmer Biomet Holdings during the fourth quarter worth $1,026,000. Liberty Mutual Group Asset Management Inc. purchased a new position in Zimmer Biomet Holdings during the fourth quarter worth $1,029,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Zimmer Biomet Holdings during the fourth quarter worth $1,147,000. Advisors Asset Management Inc. purchased a new position in Zimmer Biomet Holdings during the fourth quarter worth $1,234,000. Finally, Andra AP fonden purchased a new position in Zimmer Biomet Holdings during the fourth quarter worth $1,600,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.